Explore the advantages of continuous glucose monitors and their reliance on precise electronic components for accurate data ...

Feig and her team from the Department of Mechanical Engineering at Stanford University developed the Self-Aggregating ...

In laboratory tests, tiny implantable battery reduces size of cancer tumour by 99 per cent in two weeks A pioneering ...

A pioneering biobattery has been shown to reduce tumor growth in the body and could hold the key to a new drug-free ...

Chronic pain conditions, characterized by persistent or recurrent pain in specific parts of the body, can be highly ...

The Global On Body Drug Delivery Devices Market is projected to grow from $40.54B in 2024 to $82.74B by 2033, expanding at a CAGR of 8.6% during 2025-2033. Driven by rising chronic diseases and demand ...

Innovations in Formulation and Device Design for Enhanced Subcutaneous Delivery As Part of Europe’s leading Injectable conference series, we will assess innovations in drug product formulation ...

BiVacor announced today that it received FDA breakthrough device designation for its Total Artificial Heart (TAH) system.

A subcutaneous formulation of MSD's top-selling ... the concentrations of pembrolizumab in the body achieved using both delivery routes were comparable, with efficacy and safety measures ...

The single-rod, etonogestrel-releasing, subdermal implant (ENG implant) is the most effective, long-acting reversible method of contraception available. The failure rate of the ENG implant is 0.05 ...

Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients. This ...